/KAN.ST
KAN.ST Stock - Kancera AB (publ)
Healthcare|BiotechnologySTO
$0.30+0.00%
+$0.00 (+0.00%) • Sep 23
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KAN.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.29 – $0.30
TARGET (TP)$0.34
STOP LOSS$0.27
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$2.25
52W Low$0.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14,000 | $1.03M | $753,000 | $1.70M | $90,000 |
| Gross Profit | $14,000 | $1.03M | $393,000 | $1.38M | $63,000 |
| Gross Margin | 100.0% | 100.0% | 52.2% | 81.2% | 70.0% |
| Operating Income | $-46,161,000 | $-65,042,000 | $-51,934,000 | $-45,256,000 | $-51,810,000 |
| Net Income | $-44,566,000 | $-64,889,000 | $-52,484,000 | $-45,686,000 | $-40,500,000 |
| Net Margin | -318328.6% | -6269.5% | -6970.0% | -2681.1% | -45000.0% |
| EPS | $-0.39 | $-0.80 | $-0.88 | $-0.68 | $-1.08 |
Company Overview
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KAN.STBeat Rate
43%
Last 7 quarters
Avg Surprise
-22.7%
EPS vs Estimate
Beats / Misses
3/4
Last 12 quarters
Latest EPS
$-0.11
Q2 2025
EPS Surprise History
Q3 23
-41.5%
$-0.22vs$-0.16
Q4 23
+40.1%
$-0.13vs$-0.21
Q1 24
-51.1%
$-0.22vs$-0.15
Q2 24
+35.0%
$-0.13vs$-0.20
Q3 24
+47.1%
$-0.09vs$-0.17
Q4 24
-119.6%
$-0.09vs$0.46
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 21, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | — | — | — | — |
Q4 2025 | Nov 21, 2025 | — | — | — | — |
Q2 2025 | May 23, 2025 | — | $-0.11 | — | — |
Q1 2025 | Feb 21, 2025 | — | $-0.08 | — | — |
Q4 2024 | Nov 15, 2024 | $0.46 | $-0.09 | -119.6% | ✗ MISS |
Q3 2024 | Aug 23, 2024 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q2 2024 | May 17, 2024 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q1 2024 | Feb 23, 2024 | $-0.15 | $-0.22 | -51.1% | ✗ MISS |
Q4 2023 | Nov 17, 2023 | $-0.21 | $-0.13 | +40.1% | ✓ BEAT |
Q3 2023 | Aug 18, 2023 | $-0.16 | $-0.22 | -41.5% | ✗ MISS |
Q2 2023 | May 19, 2023 | $-0.13 | $-0.21 | -69.3% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | — | $-0.21 | — | — |
Q4 2022 | Oct 26, 2022 | — | $-0.17 | — | — |
Q3 2022 | Aug 19, 2022 | — | $-0.24 | — | — |
Q2 2022 | May 20, 2022 | — | $-0.21 | — | — |
Q1 2022 | Feb 18, 2022 | — | $-0.23 | — | — |
Q4 2021 | Nov 19, 2021 | — | $-0.31 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.17 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about KAN.ST
What is KAN.ST's current stock price?
Kancera AB (publ) (KAN.ST) is currently trading at $0.30 per share. The stock has moved +0.00% today.
What is the analyst price target for KAN.ST?
No analyst price targets are currently available for this stock.
What sector is Kancera AB (publ) in?
Kancera AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is KAN.ST's market cap?
Kancera AB (publ) has a market capitalization of $0.04 billion, making it a small-cap company.
Does KAN.ST pay dividends?
No, Kancera AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMNI.ST
Amniotics AB (publ)
$0.01
Mkt Cap: $0.0B
COALA.ST
Coala-Life Group AB (publ)
$0.02
Mkt Cap: $0.0B
COMBI.ST
CombiGene AB (publ)
$2.47
Mkt Cap: $0.0B
DIABIO.ST
Diagonal Bio AB (publ)
$0.01
Mkt Cap: $0.0B
EMPLI.ST
Emplicure AB (publ)
$0.47
Mkt Cap: $0.0B
FRISQ.ST
FRISQ Holding AB (publ)
$0.70
Mkt Cap: $0.0B
IDOGEN.ST
Idogen AB (publ)
$0.12
Mkt Cap: $0.0B
NEOD.ST
NeoDynamics AB (publ)
$0.90
Mkt Cap: $0.0B
PHARM.ST
Pharmiva AB (publ)
$0.56
Mkt Cap: $0.0B
RLS.ST
RLS Global AB (publ)
$0.45
Mkt Cap: $0.0B
Explore stocks similar to KAN.ST for comparison